Palatin Technologies News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.12.24	Palatin Announces Positive Results In Phase IIb Study Of Bremelanotide In Diabetic Nephropathy (RTTNews)
25.11.24	Palatin Completes Patient Enrollment In Phase 2 Study Of PL8177 In Ulcerative Colitis, Shares Up 16% (RTTNews)
14.11.24	Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 (RTTNews)
01.10.24	Palatin Technologies Inc. Q4 Loss Narrows (RTTNews)
25.08.24	Weekly Biotech Buzz: AADI Trims R&D Jobs, JNJ Loosens Purse Strings, FDA Snubs REGN's Myeloma Drug (RTTNews)
15.05.24	Palatin Technologies Inc. Q3 Loss Decreases (RTTNews)
02.05.24	Palatin: FDA Clears IND Application For Bremelanotide Phase 2 Study (RTTNews)
12.04.24	Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying (Benzinga)
08.04.24	Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data (Benzinga)
08.04.24	Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive (RTTNews)
28.02.24	Palatin Stock Drops As Co-Primary Sign, Secondary Sign Endpoints Not Met In PL9643 Phase 3 DED Trial (RTTNews)
15.02.24	Palatin Technologies Inc. Q2 Earnings Summary (RTTNews)
30.01.24	Palatin Technologies Prices Offering Of $10 Mln Of Shares; Stock Down Over 4% In Pre-Market (RTTNews)
20.12.23	Palatin Technologies Completes Sale Of Vyleesi To Cosette Pharma For Up To $171 Mln (RTTNews)
20.12.23	Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million (PR Newswire)
18.12.23	Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American (PR Newswire)
14.11.23	Palatin Technologies Inc. Q1 Loss decreases, but misses estimates (RTTNews)
14.11.23	Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
09.11.23	Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023 (PR Newswire)
24.10.23	Palatin Announces Closing of $5 Million Registered Direct Offering (PR Newswire)
23.10.23	Palatin Announces $5 Million Registered Direct Offering (PR Newswire)
19.10.23	Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results (PR Newswire)
18.10.23	Palatin: GLP-1 & MC4R Agonist Co-administration Data Shows Increased Weight Loss (RTTNews)
18.10.23	Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients (PR Newswire)
16.10.23	Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment (PR Newswire)
13.10.23	Palatin Receives Notice of Non-Compliance from NYSE American (PR Newswire)
28.09.23	Palatin Technologies Inc. Q4 Loss decreases, but misses estimates (RTTNews)
28.09.23	Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update (PR Newswire)
22.09.23	Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023 (PR Newswire)
07.09.23	Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
07.09.23	Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease (PR Newswire)
10.08.23	Palatin Initiates Clinical Program For Bremelanotide Co-Formulated With PDE5i For ED Treatment (RTTNews)
10.08.23	Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment (PR Newswire)
08.08.23	Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study (PR Newswire)
07.08.23	Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi® (PR Newswire)
04.08.23	Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference (PR Newswire)
11.07.23	Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results (PR Newswire)
30.05.23	Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference (PR Newswire)
16.05.23	Palatin Technologies Inc. Q3 Loss Narrows (RTTNews)
16.05.23	Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
11.05.23	Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 (PR Newswire)
09.05.23	Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference (PR Newswire)
08.05.23	Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar (PR Newswire)
01.05.23	Palatin Technologies to Host Key Opinion Leader Webinar (PR Newswire)
27.04.23	Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference (PR Newswire)
25.04.23	Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma (PR Newswire)
19.04.23	Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results (PR Newswire)
18.04.23	Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences (PR Newswire)
02.03.23	Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

14.02.22		Ausblick: Palatin Technologies präsentiert Bilanzzahlen zum jüngsten Jahresviertel
14.11.21		Ausblick: Palatin Technologies präsentiert Quartalsergebnisse

14.02.22

Ausblick: Palatin Technologies präsentiert Bilanzzahlen zum jüngsten Jahresviertel

14.11.21

Ausblick: Palatin Technologies präsentiert Quartalsergebnisse

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Palatin Technologies Inc

Aktien Top/Flop

Palatin Technologies Peer Group Nachrichten

Meistgelesene Nachrichten